Related Experiment Videos
Therapy of chronic myelogenous leukemia
M Talpaz1, H Kantarjian, K McCredie
1Department of Clinical Immunology and Biological Therapy, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77030, USA.
Cancer
|February 1, 1987
Summary
Interferon alfa-2a effectively treats chronic myelogenous leukemia (CML) by inducing remissions and suppressing the Philadelphia (Ph1) chromosome. This breakthrough allows for the emergence of normal karyotype cells in CML patients.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Interferons exhibit antiviral, antiproliferative, and immunomodulatory properties.
- Limited interferon availability hindered clinical investigation for chronic myelogenous leukemia (CML).
Purpose of the Study:
- To investigate the efficacy of interferon alfa-2a in treating CML.
- To assess the capacity of interferon alfa-2a to suppress CML Philadelphia (Ph1) clones and restore normal karyotype cells.
Main Methods:
- Production of large quantities of bacterially synthesized human alpha-A interferon (interferon alfa-2a) following gene cloning.
- Clinical trials involving minimally treated, benign-phase CML, Ph1-positive patients.
Main Results:
- Interferon alfa-2a demonstrated effectiveness in inducing hematologic remissions in most CML patients.
- Treatment led to Ph1 chromosome suppression in bone marrow and the emergence of normal karyotype cells in some patients.
Conclusions:
- Interferon alfa-2a is an effective therapeutic agent for chronic myelogenous leukemia.
- The study highlights the potential of interferon alfa-2a in CML management and restoration of normal hematopoiesis.